Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Regenecare HA is an over-the-counter topical hydrogel manufactured by MPM Medical LLC. The product is formulated with 2% lidocaine hydrochloride as its active pharmaceutical ingredient, which provides temporary relief from pain and itching by acting as a topical anesthetic and analgesic. In addition to lidocaine, the hydrogel contains hyaluronic acid, collagen (procollagen), aloe vera, and allantoin. These ingredients work synergistically to manage wounds by moisturizing damaged tissue and supporting the natural healing processes, including granulation tissue formation, reepithelization, and remodeling. Regenecare HA is available in gel and spray forms and is indicated for minor burns, sunburn, minor cuts, scrapes, insect bites, and other minor skin irritations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Regenecare HA.